Home Technology The first drug that slows Alzheimer’s has finally received FDA approval

The first drug that slows Alzheimer’s has finally received FDA approval

by TM

Japanese drugmaker Eisai and US-based Biogen have collaborated for nearly a decade to advance research in Alzheimer’s. The FDA has now granted approval to their drug Leqembi for intravenous use, making it the first treatment that can slow the progression of the disease. While Leqembi addresses the underlying biology of Alzheimer’s by reducing amyloid plaques, it is not a cure. Unlike Aduhelm, another drug targeting plaque buildup but not yet fully FDA-approved, Leqembi has demonstrated clinical benefit in addition to reducing protein buildup. However, its high price tag of $26,500 may limit accessibility for most patients. The growing aging population in the US necessitates a focus on Alzheimer’s treatment and diagnostics.
Meta Data: {“keywords”:”Eisai, Biogen, Alzheimer’s, Leqembi, clinical benefit, amyloid plaques, Aduhelm, accessibility, Medicaid, aging population”}

Source link

You may also like

Leave a Comment

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
-
00:00
00:00
Update Required Flash plugin
-
00:00
00:00